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Abstract
Background: There is little data on the relationship between novel cardiovascular risk factors and
silent coronary artery disease (CAD) in diabetic patients. We investigated whether Lipoprotein(a),
homocysteine and apolipoprotein(a) polymorphism are associated with angiographically assessed
asymptomatic coronary artery disease (CAD) in diabetic patients.
Methods: 1,971 type 2 diabetic patients without clinical signs of cardiovascular diseases and with
a negative history of CAD were consecutively evaluated. Among them, 179 patients showed
electrocardiographic abnormalities suggestive of ischemia or previous asymptomatic myocardial
infarction. These 179 patients were subjected to a non-invasive test for CAD (ECG stress testing
and/or scintigraphy). Among patients with a highly positive stress testing (n = 19) or a positive
scintigraphy (n = 74), 75 showed an angiographically documented CAD (CAD group). Seventy-five
patients without CAD (NO CAD group) were matched by age, sex and duration of diabetes to
CAD patients. In NO CAD patients an exercise ECG test, a 48-hour ambulatory ECG and a stress
echocardiogram were negative for CAD.
Results: Lipoprotein(a) levels (22.0 ± 18.9 versus 16.0 ± 19.4 mg/dl; p < 0.05), homocysteine levels
(13.6 ± 6.6 versus 11.4 ± 4.9 mmol/l; p < 0.05) and the percentage of subjects with at least one
small apolipoprotein(a) isoform (70.7% versus 29.3%; p < 0.0001) were higher in CAD than NO
CAD group. Logistic regression analysis showed that apolipoprotein(a) polymorphism (OR:8.65;
95%CI:3.05–24.55), microalbuminuria (OR:6.16; 95%CI:2.21–17.18), smoking (OR:2.53;
95%CI:1.05–6.08), HDL (OR:3.16; 95%CI:1.28–7.81), homocysteine (OR:2.25; 95%CI:1.14–4.43)
and Lipoprotein(a) (OR:2.62; 95%CI:1.01–6.79) were independent predictors of asymptomatic
CAD.
Conclusions: The present investigation shows an independent association of Lipoprotein(a),
homocysteine and apo(a) polymorphism with silent CAD. Other studies are needed to establish
whether these parameters are suitable for CAD screening in diabetic patients.
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Background
Lipoprotein(a) -Lp(a)- and plasma total homocysteine
(tHcy) are risk factors for coronary artery disease (CAD)
[1,2]. The specific apolipoprotein of Lp(a), called apo(a),
could play a role independent of Lp(a) levels in the devel-
opment of CAD [3–8]. Among diabetic patients silent
CAD is quite frequent [9–11]. Silent CAD is a strong pre-
dictor of future coronary events and early death, particu-
larly in diabetic patients [12,13]. This suggests that the
early identification of diabetic patients with silent CAD
could permit the reduction of mortality and morbidity for
coronary events by the implementation of specific preven-
tive programs [14]. Nevertheless, the diagnosis of silent
CAD is quite difficult, since few risk factors are known. In
diabetic patients the relationship of Lp(a) and tHcy with
overt CAD has been analysed [15–22]. An association of
high Lp(a) levels and apo(a) phenotypes with silent CAD
has been found in diabetic patients with normal resting
ECG [23]. No studies investigated the relationship be-
tween Hcy and silent CAD.
In the present study we investigated whether in a group of
type 2 diabetic patients without a personal history of car-
diovascular events and without current clinical signs of
CAD Lp(a), Hcy and apo(a) polymorphism are associated
with angiographically assessed silent CAD.
Methods
Patients
We evaluated 1,971 type 2 diabetic patients to find sub-
jects with silent CAD. Exclusion criteria were: age <45 or
>70 years, symptoms of coronary events as defined by
Rose questionnaire, history of coronary events, artery
revascularization, stroke, claudicatio intermittens, heart
failure, uncontrolled hypertension (>180/100 mmHg),
significant valvular diseases, cardiomyopathy, chronic or
acute diseases, pregnancy, liver or kidney disease (creati-
nine >130 µmol/l), proteinuria (dipstick-positive pro-
teinuria or albumin excretion rate (AER) ≥300 mg/day),
diabetic proliferative retinopathy or previous photocoag-
ulation, therapy with digital, neoplasia, duration of diabe-
tes < 12 months, conditions which did not permit
maximal exercise ECG (amputation, foot wound, severe
obesity, etc). Diabetes was diagnosed according to ADA
criteria [24]. Hypertension was diagnosed according to
WHO criteria [25] or in presence of a specific treatment.
Patients with AER<30 mg/day were considered nor-
moalbuminuric; patients with AER between 30 and 299
mg/day were considered microalbuminuric.
Study protocol
The study protocol is depicted in Figure 1. All the patients
underwent a standard 12-lead resting ECG interpreted ac-
cording to Minnesota Code [26]. According to resting
ECG, patients were subdivided in four subgroups: 1) nor-
mal ECG; 2) ST-T abnormalities; 3) abnormalities sugges-
tive of infarction; 4) other abnormalities. Patients with ST-
T abnormalities underwent an exercise stress testing [27].
Subjects were requested to discontinue any antihyperten-
sive drug with antiischemic properties, including β-block-
ers and calcium channel blockers. An exercise ECG test
was considered positive if there was an ST segment depres-
sion equal to or greater than 1 mm which was planar or
downsloping and persisted for at least 80 ms after the J
point. A test was considered negative when the patient
reached 90% of the maximal predicted exercise heart rate
for age without symptoms and significant ST segment
change. When exercise ECG test was highly positive (ST
depression in 5 or more leads; >2 mm maximum ST de-
pression; a positive test with a heart rate <120; hypoten-
sion during exercise; exercise capacity <5 min) the
suspicion of CAD was considered strong. In other patients
with a positive or equivocal exercise ECG test an exercise
stress thallium scintigraphy was performed. Initial imag-
ing was made within 5 minutes after intravenous injection
of thallium-201. Four hours later, cardiac imaging was re-
peated. Five regions of the left ventricle were defined: an-
terior, apical, septal, inferior and postero-lateral. The
scintigraphy was considered positive for CAD when the
thallium scan exhibited fixed or transient uptake defects.
In patients with highly positive ECG and those with a pos-
itive scintigraphy a diagnostic coronary angiography was
recommended. Angiography was performed as previously
reported [27]. An atherosclerotic lesion was considered
significant when a stenosis ≥50% of the lumen in at least
one major vessel was documented. In patients with ECG
abnormalities suggestive of myocardial infarction an exer-
cise stress thallium scintigraphy was performed. In pa-
tients with a positive scintigraphy a diagnostic coronary
angiography was recommended. Patients with other ECG
abnormalities were excluded from the study.
Diabetic patients without CAD (NO CAD group) were se-
lected from the patients with a normal resting ECG; NO
CAD patients were matched by age, gender and duration
of diabetes to patients with angiographically documented
asymptomatic CAD (CAD group). NO CAD patients un-
derwent a stress ECG testing, a 48-hour ambulatory ECG
(Holter) monitoring and a stress exercise echocardiogra-
phy. The 48-h Holter ECG monitoring consisted of a 2
channel recording (leads V1 and V5). Real time two di-
mensional echocardiografic examinations were per-
formed before and immediately after an exercise ECG
testing. The post-exercise echocardiografic study was start-
ed immediately after the termination of the exercise (<30
s) and completed within 3 minutes. In CAD and NO CAD
patients the following five standard repeatable tests were
performed to study autonomic function [28]: heart-rate
response to Valsalva manoeuvre, heart-rate variation dur-
ing deep breathing, blood-pressure response to sustainedCardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/5
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Figure 1
The study protocol. The number (n=) of patients at each point of the flow diagram is reported. Coronary angiography was rec-
ommended in 93 subjects, but 84 angiographies were performed, since 12 patients did not give their consent.
ECG AT REST
                                                                        (n=1,971)
Normal           S-T abnormalities       Abnormalities suggestive of infarction     Other abnormalities   
 (n=1,591)                  (n=158)                                        (n=21)                                   (n=201)
   Selection of 
NO CAD patients
EXERCISE ECG TESTING
                                       (n=158)
Exclusion
Negative   Highly positive   Positive  (n=54) 
                            (n=69)          (n=19)             or equivocal or
                                                                        unconclusive (n=16)                                                              
MYOCARDIAL SCINTIGRAPHY
(n=91)
Positive                              Negative
                                                                                              (n=74)                                 (n=17)
CORONARY ANGIOGRAPHY
                                                                      (n=84)
                       Positive                                                                          Negative    
                       (n=75)                                                                              (n=9)Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/5
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handgrip, immediate heart-rate response to standing,
blood pressure to standing. The first three tests mainly in-
vestigate parasympathetic damage, while the latter two
tests evaluate damage of sympathetic system. We consid-
ered the diagnosis of impaired autonomic function in the
presence of abnormal findings in at least one of the tests
[28]. The study was approved by the ethic committee. In-
vasive testing was performed only when there was a clear
clinical indication according to the daily clinical practice
in our Institute. All patients gave their informed consent
both to perform each test and to participate in the study.
Laboratory procedures
Venous blood samples were taken from subjects after 12-
hour fasting. In subjects treated with lipid-lowering drugs
or oestrogen and progestagen, blood samples were taken
after a wash-out period of at least 3 months from above
drugs. No patient was receiving Vitamin B or folic acid
supplementation. For the quantification of Lp(a) and
tHcy and the characterization of apo(a) isoforms we used
plasma obtained by addition of EDTA and centrifugation
within 1 hour after collection. Immediately after centrifu-
gation, plasma samples were frozen and stored at -80°C.
Cholesterol, HDL and triglycerides were measured by an
automatic analyzer HITACHI 737 (Tokio-Japan). LDL was
calculated by Friedewald's formula, considering the con-
tribution of Lp(a) on LDL levels [29]. Glycated haemo-
globin (HbA1c) was measured by high-performance
liquid chromatography (Biorad, Richmond, CA). AER was
measured by nephelometry (Beckmann, Milan, Italy).
Lp(a) plasma concentrations were determined by a sand-
wich-ELISA method (Macra-Lp(a) SDI, Newark, Dela-
ware). Plasma tHcy level was measured by high-
performance liquid chromatography. Apo(a) isoforms
were detected by a high-resolution immunoblotting tech-
nique [7,30]. The investigators who performed laboratory
procedures were blind to the status of the patients (pres-
ence or absence of CAD). Physicians who analysed and/or
performed resting ECG, exercise ECG testing, myocardial
scintigraphy and coronary arteriography were blind to the
following biological parameters of the patients: levels of
Lp(a) and tHcy, apo(a) phenotypes.
Statistical analysis
By using an analysis of covariance, all data regarding lipid
parameters and tHcy were adjusted for sex, BMI, smoking,
drug intake, and presence of hypertension, microalbu-
minuria and menopause. To assess differences in choles-
terol, LDL, HDL, BMI, the Student t-test was utilized.
Because of the highly "skewed" distribution of Lp(a), tH-
cy, and triglycerides levels, to compare Lp(a), tHcy, and
triglycerides values the Mann-Whitney U-test was used.
The Pearson chi-squared test was exploited for frequency
comparison. The relationship of AER with Lp(a) levels
and tHcy levels was evaluated by Pearson's correlation co-
efficient after Log-transformation. A multiple logistic re-
gression analysis with the presence of asymptomatic CAD
as the dependent variable was performed. Odds Ratios
(ORs) were estimated and the results were given as ORs
and 95%CI. Sensitivity (probability that a test will be pos-
itive when the disease is present), specificity (probability
that a test will be negative when the disease is not
present), positive predictive value (probability that the
disease is present when the test is positive) and negative
predictive value (probability that the disease is not
present when the test is negative) have been calculated for
some parameters. Table 1 reports the schematic outcomes
of a test. Data were presented as means ± SD, unless oth-
erwise stated. P < 0.05 was considered significant.
Results
Out of the 1,971 type 2 diabetic patients, 1591 (80.7%)
showed a normal resting ECG, 158 (8.1%) ST-T abnor-
malities, 21 (1.0%) signs suggestive of infarction and 201
(10.2%) other ECG abnormalities (bundle branch block,
atrial fibrillation or other important arrythmias, atrioven-
tricular block, fascicular anterior block, left ventricular
hypertrophy).
Patients with ST-T abnormalities
Out of 158 type 2 diabetic patients with ST-T abnormali-
ties, exercise stress ECG test was positive in 73 patients,
negative in 69, equivocal or unconclusive in 16. In 19 pa-
tients the exercise ECG test was highly positive and there-
fore the angiography was recommended. Other 54
patients with a positive exercise ECG and 16 patients with
equivocal or unconclusive test underwent an exercise
Table 1: Schematic outcomes of a test
TEST CAD n NO CAD n
Positive True positive a False positive c
Negative False negative b True negative d
Sensitivity = a / (a+b); specificity = d / (c+d); positive predictive value = a / (a+c) Negative predictive value = d / (b+d)Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/5
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stress thallium scintigraphy. Among these patients, scin-
tigraphy was positive in 58 subjects. Seventy-two (17 sub-
jects with highly positive exercise ECG and 55 with a
positive scintigraphy) gave their informed consent to per-
form coronary angiography. Angiography showed a sig-
nificant atherosclerotic lesion in 65 subjects (16 with a
highly positive exercise test and 49 with a positive scintig-
raphy) and no significant lesions in 7 patients.
Patients with ECG suggestive of infarction
Out of 21 patients with ECG abnormalities suggestive of
myocardial infarction, 16 had a positive scintigraphy.
Among them, 12 gave their informed consent to perform
Table 2: Characteristics of diabetic patients with asymptomatic CAD and without CAD.
CAD NO CAD p-value
Number 75 75
Sex (M/F) 62/13 62/13 NS
Age (years) 56.6 ± 6.2 56.7 ± 6.2 NS
Duration of diabetes (years) 7.9 ± 5.7 8.0 ± 4.9 NS
BMI 26.4 ± 3.4 26.1 ± 3.7 NS
HbA1c (%) 7.8 ± 1.4 7.4 ± 1.4 NS
Cholesterol (mmol/l)
Mean 5.6 ± 0.9 5.4 ± 1.0 NS
Median 5.6 5.2
Range 3.8–9.0 3.4–8.6
LDL (mmol/l)
Mean 2.7 ± 1.0 2.5 ± 1.0 NS
Median 2.8 2.6
Range 1.0–5.9 0.5–6.0
HDL (mmol/l)
Mean 1.1 ± 0.2 1.2 ± 0.2 <0.05
Median 1.1 1.3
Range 0.6–2.0 0.9–2.1
Triglycerides (mmol/l)
Mean 1.7 ± 0.6 1.6 ± 0.6 NS
Median 1.7 1.5
Range 0.8–3.2 0.6–3.7
Microalbuminuria (%) 42.7 10.7 <0.0001
AER (mg/day)
Mean 53.0 ± 67.8 22.5 ± 37.5 <0.01
Median 25.0 10.0
Range 4.5–293.1 4.9–258.3
Smokers (%) 57.3 29.3 <0.001
Family history of CAD (%) 36.0 30.7 NS
Hypertension (%) 53.3 57.3 NS
Autonomic neuropathy (%) 29.3 22.7 NS
Lp(a) levels (mg/dl)
Mean 22.0 ± 18.9 16.0 ± 19.4 <0.05
Median 18.0 7.0
Range 0.5–85 0–88.5
Subjects with Lp(a) levels >30 mg/dl (%) 33.3% 17.3% <0.05
tHcy levels (mmol/l)
Mean 13.6 ± 6.0 11.4 ± 4.9 <0.05
Median 12.0 10.0
Range 7.4–41.1 5.1–35.6
Subjects with tHcy levels >14.0 mmol/l 
(%)
42.7 26.7 <0.05
Subjects with at least one isoform of low 
MW (%)
70.7 29.3 <0.0001
LDL = Low Density Lipoprotein; HDL = High Density Lipoprotein; BMI = Body Mass Index; AER = Albumin Excretion Rate. Lp(a) = Lipoprotein(a); 
tHcy = total homocysteine; Apo(a) = Apolipoprotein(a); CAD = Coronary Artery Disease; tHcy = total homocysteine; MW = Molecular WeightCardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/5
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coronary angiography. Angiography showed a significant
atherosclerotic lesion in 10 subjects and no significant le-
sions in two patients.
CAD and NO CAD groups
Among 75 patients with angiographically verified asymp-
tomatic CAD (CAD group), 23 subjects (30.7%) showed
a mono-vessel disease, 32 (42.6%) a bi-vessel disease, and
20 (26.7%) a multi-vessel disease. Seventy-five diabetic
patients without CAD (NO CAD group) were selected
from the 1,591 diabetic patients with a negative resting
ECG. NO CAD patients were matched by age, gender and
duration of diabetes to 75 CAD patients. In NO CAD pa-
tients exercise ECG testing, 48-h ECG Holter and stress
echocardiography were negative for CAD. Among CAD
patients, 30 (40.0%) were treated with oral agents, 31
(41.3%) with insulin, 2 (2.7%) with insulin and oral
agents, and 12 (16.0%) with diet alone. Among NO CAD
patients, 36 (48.0%) were treated with oral agents, 24
(32.0%) with insulin, none (0%) with insulin and oral
agents, and 15 (20.0%) with diet alone. No differences in
diabetes treatment were found between the groups (χ2 =
3.770; df = 3; NS). Patients receiving metformin were 25
(33.3%) among CAD patients and 31 (41.3%) among NO
CAD patients (χ2 = 1.03; df = 1; NS).
Table 2 shows biological and clinical features of patients
with and without CAD. CAD group showed a percentage
of microalbuminuric subjects and smokers significantly
greater and HDL levels significantly lower than NO CAD
group.
Glycemic control
Table 1 shows that the two study groups did not differ in
HbA1c at recruitment. In our diabetic patients HbA1c was
measured quarterly. We did not find differences in the av-
erage values of HbA1c measurements performed in the
year before the recruitment (7.8 ± 1.3 versus 7.6 ± 1.2%;
NS).
Autonomic function
Among CAD patients, 22 showed abnormal autonomic
function. In particular, in 10 patients one of the parasym-
pathetic tests was abnormal, in 8 two of the parasympa-
thetic tests were abnormal, in 2 one of the sympathetic
tests was abnormal; in 2 patients both one of the parasym-
pathetic tests and one of the sympathetic tests were abnor-
mal. Among NO CAD patients, 17 showed abnormal
autonomic function. In particular, in 10 patients one of
the parasympathetic tests was abnormal, in 6 two of the
parasympathetic tests were abnormal; in 1 patient both
one of the parasympathetic tests and one of the sympa-
thetic tests were abnormal.
Table 3: Results of a multiple logistic regression analysis with the presence of asymptomatic CAD as the dependent variable in diabetic 
patients
PREDICTORS Odds Ratio 95% Confidence Intervals p-value
MODEL 1
Microalbuminuria 7.09 2.65–18.96 <0.001
Smoking 2.72 1.17–5.85 <0.02
High Lp(a) levels 2.62 1.01–6.79 <0.05
Low HDL 2.39 1.06–5.38 <0.05
High tHcy levels 2.04 1.03–4.06 <0.05
MODEL 2
Apo(a) phenotypes 8.65 3.05–24.55 <0.001
Microalbuminuria 6.16 2.21–17.18 <0.01
Low HDL 3.16 1.28–7.81 <0.05
Smoking 2.53 1.05–6.08 <0.05
High tHcy levels 2.25 1.14–4.43 <0.05
Model 1, potential predictors: hypertension, family history of CAD, smoking, microalbuminuria, HbA1c, BMI, Lp(a), tHcy, cholesterol, triglycerides, 
LDL, HDL. Model 2, potential predictors: hypertension, family history of CAD, smoking, microalbuminuria, HbA1c, BMI, Lp(a), tHcy, cholesterol, 
triglycerides, LDL, HDL, Apo(a) phenotypes.Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/5
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Lipoprotein(a) levels, tHcy levels, and apolipoprotein(a) 
phenotypes
Table 2 shows that CAD group had Lp(a) levels, tHcy lev-
els and a prevalence of subjects with high Lp(a) levels and
high tHcy levels significantly higher than NO CAD group.
Out of the 150 patients enrolled, we detected 25 apo(a)
isoforms with an apparent MW varying from 400 to 835
kDa; 56 subjects (37.3%) showed two electrophoretic
bands, 93 (62.0%) showed only one electrophoretic
band. One patient (0.7%) of the NO CAD group had the
so-called "null phenotype" (no band detectable by elec-
trophoresis): this subject had a Lp(a) plasma concentra-
tion = 0 mg/dl. The cut-off between 640 and 655 kDa was
used to divide apo(a) isoforms of low and high MW
[5,7,17,31]. This cut-off appears to be the most efficient in
discriminating subjects at higher cardiovascular risk
linked to the apo(a) gene [31].
Table 3 shows that the percentage of subjects with at least
one apo(a) isoform of low MW was significantly greater in
CAD than in NO CAD group.
AER showed no significant correlation with Lp(a) levels
(in CAD group: r = 0.0447; NS - in NO CAD group: r =
0.0186; NS) or with tHcy levels (in CAD group: r =
0.0642; NS - in NO CAD group: r = 0.1606; NS)
Multivariate analysis
A multiple logistic regression analysis was performed with
presence/absence of asymptomatic CAD as the dependent
variable. Table 3 (model 1) shows the results of the anal-
ysis. When apo(a) phenotypes (presence of at least one
isoform of low MW = 1 / presence of only isoforms of high
MW = 0) were added to the list of potential predictors, the
analysis showed that apo(a) phenotypes, microalbuminu-
ria, smoking, high tHcy levels, and low HDL were inde-
pendent predictors of asymtomatic CAD in diabetic
patients (Table 3 model 2).
Sensitivity, specificity and positive or negative predictive
values have been calculated for Lp(a) (Sensitivity:0.33;
specificity:0.83; positive predictive value:0.66; negative
predictive value:0.55), apo(a) phenotype (Sensitivi-
ty:0.71; specificity:0.71; positive predictive value:0.71;
negative predictive value:0.71), tHcy (Sensitivity:0.43;
specificity:0.73; positive predictive value:0.62; negative
predictive value:0.56), and microalbuminuria (Sensitivi-
ty:0.43; specificity:0.89; positive predictive value:0.80;
negative predictive value:0.61). In addition, we tested the
prediction model with Lp(a), tHcy and apo(a) in combi-
nation: the presence of at least one positive test showed
the following results: sensitivity:0.87; specificity:0.45;
positive predictive value:0.61; negative predictive val-
ue:0.77)
Discussion
Diagnosing silent CAD is difficult. At the present, screen-
ing for CAD is recommended in only patients with com-
plications or with ECG abnormalities suggestive of
ischemia or infarction [14]. In patients with uncomplicat-
ed diabetes screening for CAD is unjustified, since the
probability of finding significant CAD by non-invasive
testing is low [9]. In uncomplicated patients the screening
for CAD is recommended only when two or more cardio-
vascular risk factors are present; nevertheless, this recom-
mendation does not address the potential impact of some
novel cardiovascular risk factors, including Lp(a) and
tHcy [14]. The possible association of Lp(a) and apo(a)
polymorphism with silent CAD has been recently investi-
gated in type 2 diabetic patients with normal ECG at rest
[23] No studies have analysed the possible role of tHcy. In
the present study we have analysed in a different popula-
tion (type 2 diabetic patients with abnormal resting ECG)
not only Lp(a) and apo(a) but also tHcy as potential risk
factors for silent CAD.
The present study shows that high Lp(a) levels and apo(a)
phenotypes of low MW are associated with silent CAD not
only in diabetic patients with normal ECG but also in
those with ECG abnormalities. In the multivariate analy-
sis, when apo(a) and Lp(a) were entered into the model at
the same time, apo(a) was a significant independent pre-
dictor of CAD, while Lp(a) did not. Lp(a) was a significant
predictor, when apo(a) was not entered. This behaviour of
Lp(a) was expected, considering that Lp(a) level is strong-
ly dependent on apo(a) MW [32]. Therefore our finding
confirms not only the association of Lp(a) and apo(a)
with silent CAD, but also that apo(a) polymorphism may
have a predictive power for silent CAD higher than that of
Lp(a) levels [23]. Lp(a) levels and the percentage of sub-
jects with low apo(a) phenotype found in the CAD group
are similar to those observed both in diabetic patients
with overt CAD [17] and in diabetic patients with silent
CAD and normal resting ECG [23]. This suggests that high
Lp(a) levels and low apo(a) phenotypes are associated
with angiographically assessed atherosclerotic stenosis
and that these parameters are not linked to any specific
clinical manifestation of CAD.
The original finding of the present investigation is the in-
dependent association between high tHcy levels and si-
lent CAD. Little is known about the impact of diabetes on
plasma tHcy levels [18]. It has been reported that glyc-
emia, HbA1c, diabetes duration and microalbuminuria
are not able to affect plasma Hcy [18,19]. On the contrary,
tHcy levels might be influenced by the deterioration of re-
nal function or by the therapy with metformin [18]. In our
study a bias due to the above conditions does not seem to
be likely. Indeed, the two study groups are matched by di-
abetes duration and do not show any differences in glyc-Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/5
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emic control. A deterioration of the renal function is not
present, since patients with abnormal creatinenemia or
with proteinuria were excluded from the study. There are
no differences in the percentages of subjects treated with
metformin between the two groups. At last no correla-
tions were observed between AER and tHcy levels.
Our data confirm that microalbuminuria and smoking
may predict silent CAD in people with diabetes [23]. The
present study shows an independent association between
low HDL levels and silent CAD; no previous studies found
any independent associations between lipid parameters
and presence of asymptomatic CAD [10,33,34], except for
MiSAD study, that reported an independent association
between total cholesterol and silent myocardial ischemia
in men [11]. In our survey an association between auto-
nomic neuropathy and silent CAD was not found. This
confirms that the role of autonomic neuropathy as a pre-
dictor of silent CAD remains to be clarified [14,35].
Our data show that subjects with Lp(a) or tHcy levels
higher than 30 mg/dl and 14 mmol/L respectively are 1.5
to 2 fold higher in the CAD group. Conversely, microalbu-
minuria is quite different (42.7% versus 10.7%) in CAD
and NO CAD, suggesting that microalbuminuria could be
more pertinent parameter for CAD screening. The reliabil-
ity of microalbuminuria as a marker for silent CAD seems
to be confirmed both by the logistic regression analysis
and by the prediction model. This finding is in agreement
with previous studies [23,36,37]. However, Lp(a) and
tHcy can provide additional information on the risk for si-
lent CAD, since they could favour the identification of
subjects with genetic CAD predisposition.
In the present study, diabetic subjects with negative non-
invasive testing for CAD were recruited as a control group.
The absence of abnormalities on regular testing or with
scintigraphy does not exclude non-occlusive CAD. Con-
sidering that in our control group angiography was not
performed because of evident ethical implications, we are
aware that some controls may have non-occlusive CAD.
This may influence the degree of association between risk
factors and silent CAD.
The association between some novel risk factors and silent
CAD has been observed in a selected group of diabetic pa-
tients. This does not imply that these parameters can be
used to predict the presence of silent CAD in all diabetic
subjects; indeed in our study the parameters were not
measured in the vast majority of patients. Moreover, due
to the relatively low number of patients recruited, ORs es-
timated by the logistic regression analysis are significant,
but the large intervals indicate a relatively weak precision.
In addition, sensitivity and specificity for Lp(a), tHcy, and
apo(a) polymorphism showed that none of the parame-
ters is able by itself to identify silent CAD. Lp(a), apo(a)
and tHcy seems to be quite specific, but the sensitivity of
Lp(a) and tHcy is quite low. Among the three parameters,
apo(a) polymorphism appears to be the most efficient.
The analysis of the three parameters in combination in-
creases the sensibility, but the specificity is quite low. The
present prediction model of silent CAD shows scores sim-
ilar to that previously published [23]. This suggests that, if
other larger studies confirm our findings, Lp(a), tHcy and
apo(a) may contribute to identify patients to screen for
CAD, only if used together with other recognized cardio-
vascular risk factors.
Another important problem is the lack of standardization
of apo(a) phenotyping methods and Lp(a) kits. In addi-
tion, there are no recognized standards for apo(a) [23].
For these reasons at the moment it is not possible an uti-
lization of these parameters in clinical practice.
Another problem regards the cut-off of apo(a) polymor-
phism. The cut-of between 640 and 655 kDa appeared to
be the most efficient in discriminating subjects at higher
cardiovascular risk linked to the apo(a) gene [32]. Howev-
er this cut-off has not been validated for clinical use by
other studies. So we are using the cut-off between 640 and
655 Kda for research only, but we are aware that this cut-
off cannot be used for clinical purposes.
Conclusions
The present investigation shows an association of Lp(a),
tHcy and apo(a) polymorphism with silent CAD in dia-
betic patients with ECG abnormalities. Other larger stud-
ies are needed to confirm our findings and to establish
whether Lp(a), tHcy, and apo(a) polymorphism can be
used as suitable markers for CAD screening.
Authors' contributions
CG and AG were the principal investigators, designed the
study, wrote the article, and participated in all analyses of
data; CC also performed statistical analysis; AG also per-
formed the detection of apo(a) isoforms; CF and SG par-
ticipated in the study design, collected and checked data;
PF was responsible for overall supervision of the research
and interpretation of data. All investigators have contrib-
uted to the writing the paper.
References
1. Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart
disease: a meta-analysis of prospective studies.  Circulation
2000, 102:1082-1085
2. Gerhard GT, Duell PB: Homocysteine and atherosclerosis. Curr
Opin Lipidol 1999, 10:417-428
3. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G: Apoli-
poprotein(a) phenotypes, Lp(a) concentration and plasma li-
pid levels in relation to coronary heart disease in a Chinese
population: evidence for the role of the apo(a) gene in coro-
nary heart disease. J Clin Invest 1992, 89:1040-1046Cardiovascular Diabetology 2002, 1 http://www.cardiab.com/content/1/1/5
Page 9 of 9
(page number not for citation purposes)
4. Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg F, Abe A,
Mühlberger V, Schönitzer D, Utermann G: Apolipoprotein(a)
Kringle IV repeat number predicts risk for coronary heart
disease. Arterioscler Thromb Vasc Biol 1996, 16:713-719
5. Gazzaruso C, Buscaglia P, Garzaniti A, Falcone C, Mariotti S, Savino
S, Bonetti G, Finardi F, Geroldi D: Association of lipoprotein(a)
levels and apolipoprotein(a) phenotypes with coronary heart
disease in patients with essential hypertension.  J Hypertens
1997, 15:227-235
6. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribas-
nig A, Meisl T, Konig P, Dieplinger H: The low molecular weight
apo(a) phenotype is an independent risk factor for coronary
artery disease in hemodialysis patients: a prospective follow-
up. J Am Soc Nephrol 1999, 10:1027-1036
7. Gazzaruso C, Garzaniti A, Buscaglia P, Bonetti G, Falcone C, Fratino
P, Finardi G, Geroldi D: Association between apolipoprotein(a)
phenotypes and coronary heart disease at a young age. J Am
Coll Cardiol 1999, 33:157-163
8. Paultre F, Pearson TA, Weil HFC, Rubin J, Francis CK, Marx HF,
Philbin EF, Reed RG, Berglund L: High levels of Lp(a) wth a smal
apo(a) isoform are associated with coronary artery disease
in African American and White men. Arterioscl Thromb Vasc Biol
2000, 20:2619-2625
9. Koistinen MJ: Prevalence of asymptomatic myocardial ischae-
mia in diabetic subjects. BMJ 1990, 301:92-95
10. Naka M, Hiramatsu K, Aizawa T, Momose A, Yoshozawa K, Shigemat-
su S, Ishihara F, Niwa A, Yamada T: Silent myocardial ischemia in
patients with non-insulin dependent diabetes mellitus as ad-
justed by treadmill exercise testing and coronary angiogra-
phy. Am Heart J 1992, 123:46-53
11. Milan Study on Atherosclerosis and Diabetes (MiSAD) Group: Prev-
alence of unrecognized silent myocardial ischemia and its as-
sociation with aterosclerotic risk factors in non-insulin
dependent diabetes mellitus. Am J Cardiol 1997, 79:134-139
12. Cohn PF: Prognosis for patients with different types of silent
CAD. Circulation 1987, 5:33-35
13. Weiner DA, Ryan TJ, Pearsons L, Fisher LD, Chaitman BR, Sheffield
LT, Tristani FE: Significance of silent myocardial ischemia dur-
ing exercise testing in patients with diabetes mellitus: a re-
port from the Coronary Artery Surgery Study (CASS)
Registry. Am J Cardiol 1991, 68:729-734
14. American Diabetes Association: Consensus development confer-
ence on the diagnosis of coronary heart disease in people
with diabetes. Diabetes Care 1998, 21:1551-1559
15. Ruiz J, Thillet J, Huby T, James RW, Erlich D, Flandre P, Froguel P,
Chapman J, Passa P: Association of elevated lipoprotein(a) lev-
els and coronary heart disease in NIDDM patients. Relation-
ship with apolipoprotein(a) phenotypes.  Diabetologia 1994,
37:585-591
16. Haffner SM, Moss SE, Klein BEK, Klein R: Lack of association be-
tween Lipoprotein(a) concentrations and coronary heart
disease mortality in diabetes: the Wisconsin epidemiologic
study of diabetic retinopathy. Metabolism 1992, 41:194-197
17. Gazzaruso C, Garzaniti A, Falcone C, Geroldi D, Finardi G, Fratino P:
Association of Lipoprotein(a) levels and apolipoprotein(a)
phenotypes with coronary artery disease in type 2 diabetic
patients and in non diabetic subjects. Diabet Med 2001, 18:589-
594
18. Yeromenko Y, Lavie L, Levy Y: Homocysteine and cardiovascu-
lar risk in patients with diabetes mellitus. Nutr Metab Cardiovasc
Dis 2001, 11:108-116
19. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJC, Jacobs C, Bouter
LM, Heine RJ, Stehouwer CDA: Hyperhomocysteinemia is asso-
ciated with an increased risk of cardiovascular disease, espe-
cially in non-insulin-dependent diabetes mellitus. A
population-based study. Arterioscler Thromb Vasc Biol 1998, 18:133-
138
20. Smulders YM, Rakic M, Slaats EH, Treskes M, Sijbrands EJG, Stehou-
wer CDA, Silberbusch J: Fasting and post-methionine homo-
cysteine levels in NIDDM. Diabetes Care 1999, 22:125-132
21. Okada E, Oida K, Tada H, Asazuma K, Eguchi K, Tohda G, Kosada S,
Takahashi S, Miyamori I: Hyperhomocysteinemia is a risk factor
for coronary arteriosclerosis in Japanese patients with type 2
diabetes. Diabetes Care 1999, 22:484-490
22. Kark JD, Selhub J, Bostom A, Rosenberg IH: Plasma homocysteine
and all-cause mortality in diabetes. Lancet 1999, 353:1936-1937
23. Gazzaruso C, Garzaniti A, Giordanetti S, Falcone C, De Amici E,
Geroldi D, Fratino P: Assessment of asymptomatic coronary
artery disease in apparently uncomplicated type 2 diabetic
patients. A role for lipoprotein(a) and apolipoprotein(a) pol-
ymorphism. Diabetes Care 2002, 25:1418-1424
24. The Expert Committee on the diagnosis and classification of diabetes
mellitus: Report of the Expert Committee on the Diagnosis
and classification of diabetes mellitus.  Diabetes Care 1997,
20:1183-1197
25. 1999 WHO-ISH: Guidelines for the management of hyperten-
sion. J Hypertens 1999, 17:151-183
26. Rose GA, Blackburn H: Cardiovascular survey methods. Mono-
graph series WHO 1968, 56:
27. Falcone C, De Servi S, Poma E, Campana C, Scire A, Montemartini C,
Specchia G: Clinical significance of exercise-induced silent my-
ocardial ischaemia in patients with coronary artery disease.
J Am Coll Cardiol 1987, 9:295-299
28. Ewing DJ, Clarke BF: Diagnosis and management of diabetic au-
tonomic neuropathy. BMJ 1982, 285:916-918
29. Li KM, Wilckenn DEL, Dudman NPB: Effect of serum Lipopro-
tein(a) on estimation of low density lipoprotein cholesterol
by the Friedewald formula. Clin Chem 1994, 40:571-573
30. Geroldi D, Bellotti V, Buscaglia P, Bonetti G, Gazzaruso C, Caprioli
A, Fratino P: Characterization of apo(a) polymorphism by a
modified immunoblotting technique in an Italian population
sample. Clin Chim Acta 1993, 221:159-169
31. Gazzaruso C, Garzaniti A, Buscaglia P, Bonetti G, Falcone C, Fratino
P, Finardi G, Geroldi D: Apolipoprotein(a) phenotypes and
their predictive value for coronary heart disease: identifica-
tion of an operative cut-off of apolipoprotein(a) polymor-
phism. J Cardiovasc Risk 1998, 5:37-42
32. Boerwinkle E, Leffert CC, Lin C, Lackner G, Chiesa G, Hobbs HH:
Apolipoprotein(a) gene accounts for greater than 90% of the
variation in plasma lipoprotein(a) concentration. J Clin Invest
1992, 90:52-60
33. Koistinen MJ, Huikuri HV, Horhonen UR, Linnaluoto MK, Kuusi T,
Takkunen JT, Taskinen MR: Asymptomatic coronary artery dis-
ease in diabetes: relation to common risk factor, lipopro-
teins, apoproteins and apoE polymorphism. Acta Diabetol 1994,
31:210-214
34. Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-
Vague V: Silent myocardial ischemia in patients with diabetes.
Who to screen. Diabetes Care 1999, 22:1396-1400
35. Airaksinen KEJ, Koistinen MJ: Association between silent coro-
nary artery disease, diabetic and autonomic neuropathy.
Fact or fallacy? Diabetes Care 1992, 15:288-292
36. Earle KA, Mishra M, Morocutti A, Barnes D, Stephens E, Chambers J,
Viberti GC: Microalbuminuria as a marker of silent myocar-
dial ischemia in IDDM patients. Diabetologia 1996, 39:854-856
37. Rutter MK, McComb JM, Brady S, Marshall SM: Silent Myocardial
Ischemia and microalbuminuria in asymptomatic subjects
with non-insulin dependent diabetes mellitus.  Am J Cardiol
1999, 83:27-31
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral